Jerusalem, Israel (PRWEB) June 1, 2006
Dr. Valentin Fulga, CEO of TheraVitae, Ltd, addressed delegates at Biomed Israel 2006, on the topic ‘A Paradigm Shift in the Biotech Field’. The presentation included details of the company’s broad technology platform as well as the innovative business model that TheraVitae utilizes. It also outlined the unique position that the company has gained in the adult stem cell field both scientifically and medically in addition to its achievements in expanding operations in Asia and elsewhere.
As one of the World Economic Forum Technology Pioneers, Dr. Fulga is a leading expert in his field, having almost 15 years experience in the life science industry. With the Biomed Israel 2006 conference focusing partly on cardiovascular diseases and the unmet need for innovative therapies, Dr. Fulga, in his role as developer of VesCell™, TheraVitae’s proprietary stem cell therapy for heart disease, said:” I am delighted and honored to have the opportunity to participate and present TheraVitae’s scientific and business achievements in front of such a large number of conference attendees.”
Noting the importance of the event, Jay D. Lenner Jr., Public Relations Manager at TheraVitae, added, “We were delighted to attend Biomed Israel 2006 which brought together the best and the brightest from Israel’s burgeoning life science industry, along with delegates from Asia, US, and Europe. This broad focus created a unique, exciting opportunity for industry leaders, such as Dr. Fulga, to network and for visitors from abroad to become acquainted with Israel’s dynamic life sciences industry.”
About the Biomed Israel Conference 2006
The annual Biomed Israel conference, held from 29-31 May 2006, attracted delegates from both Israel and abroad to this showcase event for the Israeli life sciences industry. Academics, business leaders and researchers from European and American companies and universities led the list of keynote speakers whilst other noted presenters spoke on advances in treatments and technologies, and their visions of the new frontiers in the life sciences field.
Biomed Israel 2006 Website: http://www.biomed-israel.com
TheraVitae is a private, multinational company focused on using stem cells from the patient's own blood in order to treat a variety of disorders, especially cardiovascular diseases. The company has developed a proprietary stem cell technology called VesCell™ that is currently being used by hospitals in Thailand to treat patients with heart disease. TheraVitae is based in Bangkok, Thailand, Kiryat Weizmann, Israel, Toronto, Canada, Taipei, Taiwan and Hong Kong.
Additional Information on Stem Cell Therapy:
36/72 PS Tower, 21/Fl., Sukhumvit 21, Klongtoey Nua, Bangkok 10110
7 Pinhas Sapir Street P.O. Box 4049, Ness Ziona 74140, Israel